logo
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors

Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors

National Post17-07-2025
Article content
BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors.
Article content
These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk.
Article content
An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston.
Article content
Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG.
Article content
'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.'
Article content
About Elucid
Article content
Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit elucid.com.
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Article content
Article content
Sam Choinski
Article content
Article content
Article content
Article content
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

N.S. public health reporting 30 cases of measles in northern part of province
N.S. public health reporting 30 cases of measles in northern part of province

CTV News

time7 hours ago

  • CTV News

N.S. public health reporting 30 cases of measles in northern part of province

A dose of the measles, mumps, and rubella (MMR) vaccination awaits the next patient during a vaccine clinic in St. Thomas, Ont., on Tuesday, March 4, 2025. THE CANADIAN PRESS/Geoff Robins HALIFAX — Nova Scotia Health says there are now 30 cases of measles in the northern part of the province. The health agency had reported a single case on July 7 in the northern zone, and says it is believed that all 30 infections stem from travel within Canada to regions where measles is known to be circulating. 'Currently, new cases are mainly found in large households and specific, small communities with close contact,' said a Thursday statement from Nova Scotia Health. Health officials said the rise in cases was expected because it's common for secondary infections to appear within seven to 21 days after initial measles cases are identified. Eight of 30 cases in the northern zone have been lab-confirmed and the remaining are considered confirmed based on patients' household exposure and symptoms. Despite the rise in infections, the risk to the general public is still considered low. The provincial health agency is reminding Nova Scotians that the best protection against measles is vaccination, and every person born after 1970 should have two doses of the measles-mumps-rubella vaccine after their first birthday. Nova Scotia's Department of Health says 93.4 per cent of children who turned two years old in 2024 had received one dose of the measles vaccine, and 78.6 per cent were fully vaccinated with two doses. A spokesperson with the department says actual measles vaccination rates in Nova Scotia may be higher 'because of under-reporting.' Scientists, meanwhile, say that a population needs a vaccination rate of 95 per cent — with two doses — to stop measles from spreading. In May, a single case of measles was reported in the Halifax Regional Municipality, but there were no secondary infections identified with the original case, now considered 'resolved.' This report by The Canadian Press was first published July 24, 2025. By Lyndsay Armstrong

Increase in measles virus detected through wastewater surveillance: WECHU
Increase in measles virus detected through wastewater surveillance: WECHU

CTV News

time7 hours ago

  • CTV News

Increase in measles virus detected through wastewater surveillance: WECHU

The Windsor-Essex County Health Unit has sent reminders to school-aged children who are overdue for the measles, mumps, and rubella (MMR) vaccine after an increase in the virus in wastewater surveillance in the region. WECHU says while no direct link has been established between the wastewater signal and school-aged populations, the signal serves as a reminder of the importance of maintaining high community immunization coverage to protect children.' Wastewater surveillance is one of the tools we use to monitor public health trends,' said Dr. Mehdi Aloosh, WECHU medical officer of health. 'Although clinical measles cases remain low, the presence of the virus back in the wastewater suggests that we must remain vigilant.'WECHU is offering catch-up immunization clinics throughout the summer to help families in need of support with immunizations. 'We want to make it as easy as possible for families to access this important vaccine,' said Dr. Aloosh. 'With the school year approaching and the measles virus detected in wastewater, this is a timely opportunity to ensure our community remains protected against measles and other vaccine-preventable diseases.' Residents are encouraged to check their immunization records and contact their healthcare provider or WECHU for help.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store